The molecular pathogenesis of renal cell carcinoma (RCC) is poorly understood. Whole-genome and exome sequencing followed by innovative tumorgraft analyses (to accurately determine mutant allele ratios) identified several putative two-hit tumor suppressor genes, including BAP1. The BAP1 protein, a nuclear deubiquitinase, is inactivated in 15% of clear cell RCCs. = 3 × 10 −5 ) , and combined loss of BAP1 and PBRM1 in a few RCCs was associated with rhabdoid features (q = 0.0007). BAP1 and PBRM1 regulate seemingly different gene expression programs, and BAP1 loss was associated with high tumor grade (q = 0.0005). Our results establish the foundation for an integrated pathological and molecular genetic classification of RCC, paving the way for subtype-specific treatments exploiting genetic vulnerabilities.
Kidney cancer is estimated to have been diagnosed in over 60,000 individuals in the United States in 2011 (ref. 1) . Most kidney tumors are RCC, and 70% are the clear cell type (ccRCC) 2 . Despite recent advances 3 , when metastatic, ccRCC remains largely incurable. ccRCC is characterized by inactivation of the VHL gene (encoding the von Hippel-Lindau protein) [4] [5] [6] . VHL, which is on chromosome 3p25, is a two-hit tumor suppressor gene. One allele is typically inactivated through a point mutation (or indel), and the other is inactivated through a large deletion resulting in loss-ofheterozygosity (LOH) 7, 8 . Also on chromosome 3p is PBRM1 (encoding Polybromo 1), which is frequently mutated in ccRCC 9 . Other genes implicated in ccRCC development include SETD2 (ref. 10) , KDM5C 10 and KDM6A 11 , but the mutation frequency of each is estimated at <5% (refs. 10, 11) .
ccRCCs are classified into low-and high-grade tumors 12 , and nuclear grade is an important prognostic factor 13, 14 . High-grade tumors have mammalian target of rapamycin (mTOR) complex 1 (mTORC1) activation 15 . mTORC1 is a critical regulator of cell growth and is negatively regulated by a complex formed by the tuberous sclerosis complex 1 (TSC1) and 2 (TSC2) proteins 16 . MTOR 9, 10, 17 and TSC1 (ref. 18 ) are both mutated in sporadic ccRCC; however, mutations are infrequent 19 , and the genetic determinants of tumor grade remain largely unknown.
RESULTS

Identification of candidate two-hit tumor suppressor genes
We sequenced the genome of a sporadic, high-grade ccRCC and paired normal sample to >94% coverage and a mean depth of ≥35× ( Supplementary Figs. 1 and 2) . We found 6,571 somatically acquired single-nucleotide mutations or indels, including 59 in protein-coding regions ( Supplementary Table 1 ). Every mutation evaluated was confirmed by Sanger sequencing ( Table 1 and Supplementary  Table 2 ). However, mutant allele ratios (MARs)-the fraction of mutant over mutant and wild-type alleles for each mutation-were low; few mutations reached a MAR of 0.5 (expected for heterozygous mutations), and no mutations reached 1 (expected for mutations accompanied by LOH) ( Table 1 and Supplementary Table 2 ). For VHL, the MAR was 0.52 ( Fig. 1a and Table 1 ), which suggested a heterozygous mutation. However, these results conflicted with DNA copy-number analyses showing that one copy of 3p was lost ( Fig. 1b) . We attributed the low MARs to tumor contamination by normal stroma. Contamination occurred despite careful sample selection (Supplementary Fig. 2c ).
Tumor implantation in mice expands the neoplastic compartment, whereas human stroma is replaced by the host 20 . Therefore, tumorgrafts may be used to calculate MARs with accuracy. RCC tumors implanted orthotopically in mice preserve the characteristics of A r t i c l e s human tumors 21 . We performed Sanger sequencing of mutated genes in a tumorgraft derived from the index subject's tumor using humanspecific primers. In comparison to tumor MAR (MAR T ) values, tumorgraft MAR (MAR TG ) values often increased to ~0.5, and, for several genes including VHL, they reached 1 (Table 1, Supplementary  Fig. 3 and Supplementary Table 2 ).
To determine whether MAR TG values reflected those expected in the index subject's tumor, we asked whether a correlation existed between MAR TG and corresponding regional DNA copy numbers in the tumor (Fig. 1b, Table 1 and Supplementary Table 2 ). A correlation was found with MAR TG (P = 1.3 × 10 −5 ) but not with MAR T (P = 0.054). These data suggest that MARs in tumors are more accurately determined by evaluating tumorgrafts. Consistent with the notion that tumorgrafts represent largely pure populations of human tumor cells, paired copy numbers (PCNs) and allele-specific copy numbers (ASCNs) in tumorgrafts more closely approached integer values ( Fig. 1b, Table 1 and Supplementary Table 2 ).
To identify putative two-hit tumor suppressor genes, we searched for genes with MAR TG values of ~1. Some genes (STK40, UBE3B, HS6ST3, STK24, C1orf167, ADAMTSL1 and C14orf43) were in regions of deletion (PCN TG values of ~1), whereas others (CRISPLD1, TMEM151A, TREH and CTNND1) were in areas of copy-neutral LOH (PCN TG values of ~2; tumorgraft ASCN min values of ~0 and ASCN max values of ~2) ( Fig. 1b and Table 1 ). Because mutations in regions of copyneutral LOH could be either homozygous (for example, CRISPLD1) or heterozygous (for example, ZNF434) ( Fig. 1b and Table 1) , accurate MARs were essential to establish whether mutated genes were putative two-hit tumor suppressors.
Accurate MARs were also helpful in inferring whether, in areas of duplication (PCN TG of ~3), the allele amplified was mutated (for example, GFPT2; MAR TG = 0.65 (expected 0.66)) or wild type (for example, DIAPH1; MAR TG = 0.31 (expected 0.33)) ( Table 1 ). In the case of GFPT2, the mutation may have preceded the duplication, whereas in the case of DIAPH1, the mutation is likely to have followed the duplication. Thus, analyses in tumorgrafts identified candidate tumor suppressor genes and shed light on the temporal sequence of mutation acquisition.
Evaluation of somatically mutated genes in a discovery cohort
Twenty-one genes mutated in the sequenced ccRCC tumor and not previously examined by the Sanger Institute 10 were sequenced in a discovery set of 76 ccRCCs, and mutations were examined in the corresponding normal samples ( Supplementary Table 3 ). As determined by VHL sequencing, which revealed somatically acquired mutations in 79% of tumors (Supplementary Data 1), sensitivity for mutation detection was excellent. Several putative two-hit tumor suppressor genes were mutated at higher than expected frequencies, including CRISPLD1, which was mutated in two additional tumors (q = 0.044), and TMEM151A, mutated in three additional tumors (q = 0.005). In addition, several other genes were recurrently mutated, including OCA2 and ND1 (also known as MT-ND1) ( Supplementary Table 4 ). Germline mutations in OCA2 cause autosomal recessive oculocutaneous albinism type 2, and the two somatic mutations we identified (encoding p.Pro211Leu and p.Val443Ile alterations; Supplementary  Table 4 ) are known disease-causing mutations 22, 23 . Two additional somatically acquired mutations were found in mitochondrial ND1 ( Supplementary Table 4 ), a gene mutated in oncocytomas, a benign tumor type 24 . The presence of these mutations in ccRCC suggests that oncocytomas could transform into malignant tumors. Transformation may result from VHL inactivation, which was observed in all the tumors with somatic ND1 mutations (Supplementary Data 1). VHL inactivation could change the morphological appearance of the tumor by affecting cellular metabolism and angiogenesis. In addition, three mutations were identified in TSC1, which we previously reported 18 .
Exome sequencing identifies two-hit tumor suppressor gene BAP1
We performed exome sequencing of seven ccRCC primary tumors, including six of high grade, and corresponding normal samples. A metastasis from one affected individual was also sequenced. We found 345 somatically acquired mutations ( Supplementary Table 5 ). In the tumor-metastasis pair, we observed 37 and 39 mutations, respectively, and 32 were shared.
To determine the accuracy of the mutations called, we performed Sanger sequencing. If concordance was >95%, Sanger sequencing of 82 mutations would predict >90% accuracy for the whole cohort. npg A r t i c l e s Among 82 randomly selected mutations, 78 were confirmed with an accuracy of >95% (Supplementary Table 6 and Supplementary Data 2). For 5 tumors, there were tumorgrafts available, and sequencing analyses of mutated genes therein uncovered 16 potential two-hit tumor suppressor genes (Supplementary Table 6 ). We focused on ten genes mutated in at least two tumors (Supplementary Table 7 ). All mutations were validated by Sanger sequencing. Whereas MAR T analysis failed to identify any putative twohit tumor suppressors, another gene in addition to VHL and PBRM1, BAP1, showed MAR TG values of ~1 ( Supplementary Table 7 ).
BAP1 sequencing in the discovery set of 76 ccRCCs identified 11 nonsynonymous mutations, including 10 confirmed to be somatically acquired ( Table 2) . Examination of a validation ccRCC set (n = 92) with corresponding normal samples uncovered 11 additional nonsynonymous mutations, including 10 that were somatically acquired ( Table 2) . Two mutations in tumors without matching normal samples were truncating and likely deleterious. Altogether, the BAP1 mutation rate was 14% (24/176 tumors). BAP1 encodes a nuclear deubiquitinase (DUB) of the ubiquitin C-terminal hydrolase (UCH)-domain containing family [25] [26] [27] that is mutated in both uveal 28 and cutaneous 29 melanoma, as well as in mesothelioma 30 . In ccRCC, most mutations were predicted to truncate the protein, and mutations were enriched in sequences encoding the UCH domain ( Fig. 2a,b ).
Development of a clinical assay for BAP1 detection
As most mutations were truncating, we developed in a laboratory with Clinical Laboratory Improvement Amendments (CLIA) certification an immunohistochemistry (IHC) test for the presenceabsence of BAP1 protein. Genetically characterized ccRCC samples validated by protein blot were used as controls ( Fig. 2c,d) . Scoring was performed by a clinical pathologist who was blinded to the BAP1 genotype. IHC results were interpretable in 175 out of 176 tumors. Nuclear BAP1 was detected in 150 tumors, and 148 were wild type for BAP1 ( Supplementary Fig. 4 ). The two discordant samples had missense mutations (encoding p.Gly13Val and p.Phe170Leu changes). Twenty-five samples were negative by IHC, and 22 of these had BAP1 mutations. Analysis of an IHC-negative sample that had wild-type BAP1 by protein blot failed to reveal detectable BAP1 protein, suggesting that other mechanisms exist to inactivate BAP1. Overall, the positive and negative predictive values of the IHC test were ~100% and 98.6%, respectively.
Structural analyses of BAP1 missense mutations
To evaluate the effects of BAP1 missense mutations in a structural context, we generated a BAP1 protein model on the basis of the related family members Uch-L3 and Uch37 (Fig. 2b) . Because ubiquitin binding orders a significant portion of the protein, the UCH domain 1  2  3  4  5  6  7  8  9  10  11  12  13 14 15 16 17 18 19 20 2122   0 npg A r t i c l e s of BAP1 was modeled after that of Uch-L3 bound to ubiquitin (Protein Data Bank (PDB) 1xd3). The interaction with the ULD domain was built by superimposing that of Uch37 (PDB 3ihr). Four alterations abrogated protein expression: three were predicted to destabilize the protein (p.Val43Gly and p.Leu112Pro removed side chains that contribute to the hydrophobic core, and p.Ala95Pro disrupted the backbone of a central α helix), and the fourth (p.His144Asn) disrupted the position of a flexible loop ( Fig. 2b) . Two alterations did not abrogate protein expression (p.Gly13Val and p.Phe170Leu). These amino-acid changes disrupted side chains implicated in either an intramolecular interaction with the ULD domain (Gly13) or ubiquitin binding (Phe170) and highlight the importance of these interactions for tumor suppressor function.
BAP1 suppresses RCC cell proliferation
Studies of the role of BAP1 in cell proliferation have given conflicting results [25] [26] [27] [30] [31] [32] [33] . To examine BAP1 in an appropriate context, ccRCC cell lines were sought in which natural selection had led to BAP1 inactivation. Among 12 RCC cell lines initially examined, only 769-P had a BAP1 mutation (Supplementary Table 8 ). The mutation (c.97T>G; p.Tyr33Asp) disrupted a residue binding ubiquitin and did not abrogate protein expression ( Figs. 2b and 3a) .
To determine the role of BAP1, 769-P cells were reconstituted with epitope-tagged wild-type BAP1 (or an empty vector control). BAP1 repressed cell proliferation without causing apoptosis ( Fig. 3a and data not shown). However, BAP1 did not completely abrogate cell proliferation.
To determine whether endogenous, mutant BAP1 acted in a dominantnegative fashion, we depleted endogenous BAP1 using small hairpin RNA (shRNA). However, depletion of mutant BAP1 did not increase the effects of ectopically expressed wild-type BAP1, indicating that mutant BAP1 did not function in a dominant-negative fashion (Fig. 3b) .
BAP1 deubiquitinates H2AK119ub1 in renal cancer cells
The protein encoded by the BAP1 ortholog in Drosophila melanogaster, Calypso, targets monoubiquitinated histone H2A (H2Aub1) 34 . An examination of H2AK119ub1 levels in 769-P cells reconstituted with wild-type BAP1 showed downregulation of basal H2Aub1 levels, indicating that mammalian BAP1 deubiquitinates H2A in renal cancer cells ( Fig. 3c) .
HCF-1 binding is required for suppression of cell proliferation
BAP1 interacts with host cell factor-1 (HCF-1) 31, 33, 35 , which serves as a scaffold for several chromatin-remodeling complexes 36 . HCF-1 binds to multiple transcription factors, including several E2Fs 37,38 , and recruits histone-modifying enzymes, such as Set1/MLL1 histone methyltransferases [39] [40] [41] , LSD1 histone demethylase 42 , Sin3 histone deacetylase 39 and MOF histone acetyltransferase 43 .
We asked whether BAP1 interacted with HCF-1 in 769-P cells. An interaction was confirmed by reciprocal immunoprecipitation experiments ( Fig. 3d) . Notably, HCF-1 immunoprecipitation depleted BAP1 from cell extracts to the same extent as BAP1 immunoprecipitation, suggesting that, as in other cell types 35 , the majority of BAP1 in renal cancer cells is bound to HCF-1 ( Fig. 3d ). BAP1 has been proposed to deubiquitinate HCF-1 (refs. 31,33) and regulate HCF-1 levels 31 , but, consistent with other reports 33 , HCF-1 levels were similar in BAP1-deficient and -reconstituted 769-P cells (Fig. 3d) .
We mutated sequences in BAP1 encoding the HCF-1 binding motif and evaluated this mutant (HBM) in cell proliferation assays. HBM suppressed HCF-1 binding and compromised the inhibitory effect of BAP1 on cell proliferation (Fig. 3e) . However, the HBM mutant did not differ from wild-type BAP1 in its ability to deubiquitinate histone H2A ( Fig. 3f) . Thus, BAP1 binds to HCF-1, and binding to HCF-1 but not H2Aub1 deubiquitination is important for the inhibition of cell proliferation.
Next, we performed gel-filtration chromatography to further examine BAP1-containing complexes. Extracts from 769-P cells expressing either an empty vector or wild-type BAP1 were fractionated using a size-exclusion column and subjected to protein blotting. Most BAP1 was found in complexes of >1 MDa and eluted with HCF-1 ( Supplementary Fig. 5 ).
BAP1 loss sensitizes RCC cells to radiation and PARP inhibitors
BAP1 is phosphorylated following DNA damage 44, 45 , and we asked whether BAP1 loss affected the response to γ-irradiation. 769-P cells with or without wild-type BAP1 showed a similar pattern of foci of Rad51 and H2AX phosphorylated at Ser139 (γH2AX) (Supplementary Fig. 6a ). However, BAP1-deficient cells were more sensitive to ionizing radiation ( Supplementary Fig. 6b ), and fewer colonies formed in clonogenic assays (Supplementary Fig. 6c ). In addition, BAP1 loss sensitized cells to the PARP inhibitor olaparib ( Supplementary Fig. 6d,e ).
We examined four additional ccRCC cell lines ( Supplementary  Table 8 ). UMRC6 lacked BAP1 protein and had a frameshift mutation (c.430delC) ( Supplementary Fig. 7a,b) . As in 769-P cells, (i) cell proliferation was inhibited by wild-type BAP1 and substantially less so by an HBM mutant, (ii) the HBM mutant reduced H2Aub1 levels, (iii) BAP1 cofractionated with HCF-1, and (iv) restoration of BAP1 protected UMRC6 cells against genotoxic death (Supplementary Fig. 7 ).
BAP1 binds HCF-1 and elutes with HCF-1 in tumorgrafts
The usefulness of RCC cell lines is limited by the development of mutations and copy-number alterations as tumor cells adapt to npg growth in culture 7, 46 . Divergence from tumors may be particularly pronounced with respect to epigenetic regulation, as growth conditions of cell lines and tumors are very different. In contrast, the pattern of gene expression in tumors is reproduced in tumorgrafts growing orthotopically in mice 21 , and tumorgrafts, like cell lines, represent a renewable source of tumor material. To determine whether the interaction of BAP1 with HCF-1 was physiologically relevant, we analyzed tumorgrafts. As in cell lines, BAP1 was bound to and cofractionated with HCF-1 (Fig. 4a,b) . In addition, we examined whether there was a correlation between BAP1 mutation and H2Aub1 levels in tumorgrafts, but no such correlation was observed ( Fig. 4c) . Taken together, these data show that the binding of BAP1 to HCF-1 is likely to be important for BAP1-mediated suppression of RCC development.
BAP1 loss is associated with high tumor grade
Deep-sequencing studies were largely focused on high-grade tumors. An analysis of all 176 tumors examined showed that BAP1 loss correlated with high Fuhrman nuclear grade (q = 0.0005) ( Supplementary  Data 1) . Because nuclear grade is associated with mTORC1 activation 15 , we tested whether a correlation existed between BAP1 loss and mTORC1 activity. As determined by the phosphorylation of both S6 and 4E-BP1, BAP1 loss was correlated with mTORC1 activation (q = 3 × 10 −4 and 0.029, respectively) ( Fig. 5a and Supplementary  Data 1) . This association did not seem to be direct, however, and similar levels of mTORC1 activation were observed in BAP1-deficient and wild-type BAP1-reconstituted cells (Supplementary Fig. 8 ).
BAP1 and PBRM1 mutations anticorrelate in ccRCC
To explore whether a relationship existed between loss of BAP1 and PBRM1, we first developed an IHC assay for PBRM1 (also known as BAF180) (Fig. 5a) . Evaluation of the 176 tumors showed confident PBRM1 staining for 146 samples, and 53% were negative for PBRM1 (Supplementary Data 1) . As PBRM1 was lost in ~50% of tumors, BAP1 loss should distribute equally between PBRM1-expressing and -deficient tumors. However, only 4 of 21 BAP1-deficient tumors were also deficient for PBRM1 ( Supplementary Fig. 9a) . These results suggest that PBRM1 and BAP1 loss are anticorrelated in tumors (P = 7 × 10 −4 ).
To explore this further, we sequenced PBRM1 in the 176 ccRCCs. We identified 94 somatic mutations, including 6 missense mutations (Supplementary Data 1) . Structural analyses of the effects of these mutations are shown in Supplementary Figure 10 . We correlated sequencing data with the results from IHC: 90% of samples that were negative for PBRM1 by IHC had a mutation, and 90% of the samples that were positive had wild-type sequence (P = 4 × 10 −23 ; npg A r t i c l e s Supplementary Fig. 9b ). An analysis of BAP1 and PBRM1 mutations in tumors revealed that only 3 of 24 samples with BAP1 mutations had a somatically acquired PBRM1 mutation ( Supplementary  Fig. 9c ). Thus, mutations in these two genes were found to anticorrelate in tumors (P = 3 × 10 −5 ). For comparison, we evaluated the distribution of mutations in SETD2 and KDM5C with respect to PBRM1 mutations in ccRCCs from the Sanger Institute 9,10 . Among 348 ccRCCs genotyped for PBRM1, 15 mutations in SETD2 were observed, and these mutations were distributed equally between tumors with mutant and wild-type PBRM1 (in 8 and 7 tumors, respectively; Supplementary Data 3). KDM5C mutations were similarly distributed across tumors with mutant and wild-type PBRM1 (in five and four tumors, respectively; Supplementary Data 3) .
Combining the IHC and mutation data, 5 out of 27 BAP1-deficient tumors were found to also be deficient in PBRM1. Assuming a binomial distribution of BAP1 loss, these data indicate that simultaneous inactivation of BAP1 and PBRM1 is negatively selected for in tumors (P = 0.0008). Notably, however, loss of BAP1 or PBRM1 was observed in 70% of ccRCCs ( Fig. 5b) .
To obtain further insight into the relationship between BAP1 and PBRM1, we performed gene expression analyses. We grouped tumors and tumorgrafts according to their BAP1 and PBRM1 status and evaluated differences with respect to wild-type tumors and tumorgrafts (Fig. 5c ). Probe sets (probes) that we had previously determined, using tumorgrafts, to be driven by non-neoplastic cells 21 were excluded from the analysis. We identified 1,451 probes that were deregulated in BAP1-deficient tumors relative to tumors that were wild type for both BAP1 and PBRM1 (q < 0.05) ( Supplementary  Data 4) . A similar number of probes distinguished PBRM1-deficient tumors (Supplementary Data 4) . These two data sets had 94 probes in common (Fig. 5d) . However, the overlap expected to occur at random Tumorgrafts   BAP1   TG158  TG24  TG79  TG127  TG143  TG144  TG164  TG26  TG115 npg was 67. Similarly, pathway analyses of the two expression signatures showed little overlap. These results suggest that BAP1 and PBRM1 do not function in the same pathway and that the tumorigenic advantage to mutating BAP1 and PBRM1 is context dependent. Further supporting the notion that loss of BAP1 and PBRM1 in tumors is not equivalent, analyses of the 176 tumors showed that PBRM1 loss was not associated with high tumor grade (q = 0.26) (Supplementary Data 1) . In the 348 ccRCC tumors sequenced by the Sanger Institute 9,10 (Supplementary Data 3) , we found a non-significant correlation between PBRM1 loss and low tumor grade (P = 0.074). Furthermore, when focusing the analyses of the 176 tumors on those that had exclusively lost PBRM1, a statistically significant correlation with low tumor grade was found (q = 0.025).
Tumors with loss of BAP1 and PBRM1 have rhabdoid features
A few tumors had loss of both BAP1 and PBRM1 (n = 5) (Supplementary Data 1) . Although co-occurrence of mutations in tumors may not indicate their simultaneous presence in the same cell and there is substantial mutation heterogeneity in RCC 17, 47 , in two tumors for which tumorgrafts were available, MAR TG values for both BAP1 and PBRM1 were ~1, and no wild-type alleles were detected (data not shown). These data suggest that the two mutations were indeed present in the same tumor cells and highlight another application of tumorgrafts.
Tumors deficient in both BAP1 and PBRM1 were uniformly of high grade and showed characteristic features: abundant acidophilic cytoplasm, eccentric nuclei and prominent macronucleoli (Fig. 5a) . These features were consistent with rhabdoid morphology 48 , a form of dedifferentiation portending aggressive tumor behavior 49 . They were present in all tumors for which there was sufficient material for analysis (4/5), and, although not unique to tumors deficient in both BAP1 and PBRM1, the association was significant (q = 0.0007; Supplementary Data 1).
DISCUSSION
These results implicate BAP1 as a tumor suppressor in ccRCC and establish the foundation for a molecular genetic classification of RCC. We show that 70% of ccRCCs lose either BAP1 or PBRM1, that tumors tend to segregate into BAP1-or PBRM1-deficient subtypes and that BAP1 loss but not PBRM1 loss is associated with high tumor grade. BAP1 functions as a two-hit tumor suppressor in ccRCC, and, consistent with this, mutant BAP1 does not act in a dominant-negative fashion. Both copies of BAP1 are also lost in melanoma 28, 29, 50 and mesothelioma 30, 51 . Although the number of RCC samples with BAP1 mutations is small, it is notable that no second-hit point mutations or indels were observed. In contrast, both BAP1 alleles may be inactivated through a point mutation (or indel) in mesothelioma 51 . We speculate that the different modes of inactivation of the second BAP1 allele reflect tissue-specific tumor suppressor gene cooperativity. Indeed, in ccRCC, 3p loss may simultaneously inactivate several genes suppressing renal tumorigenesis, including, most importantly, VHL, which is rarely mutated in other tumor types. In metastatic uveal melanoma, whole chromosome 3 losses are frequent, and other melanoma metastasis suppressors may exist on 3q. Thus, the deletion architecture of tumors may reflect tissue-specific cooperativity of tumor suppressor genes.
We propose that subsequent to a VHL mutation, which likely represents an early event in tumorigenesis 17 , the loss of 3p leaves cells vulnerable to the loss of the remaining PBRM1 or BAP1 allele. The acquisition of a PBRM1 or BAP1 mutation may set the course for ccRCCs with different properties. PBRM1 and BAP1 likely affect different epigenetic programs, and BAP1 loss is associated with high tumor grade and mTORC1 activation. Notably, whereas mutations in SETD2, which is also at 3p, seem to distribute equally between PBRM1deficient and wild-type tumors, this is not the case for BAP1 mutations. PBRM1 and BAP1 mutations anticorrelate in ccRCC. These data suggest that there is a genetic context to tumor suppressor function and that simultaneous loss of BAP1 and PBRM1 in most tumors is disadvantageous.
The clinical implications of BAP1 loss remain to be explored. As BAP1 loss was associated with high tumor grade and correlated with metastasis development in uveal melanoma 28 , BAP1 loss in ccRCC may be associated with poor prognosis. From a therapeutic standpoint, whereas RCC is considered radioresistant, BAP1deficient tumors may be more sensitive. Evaluating the prognostic and therapeutic implications of BAP1 loss will be greatly facilitated npg A r t i c l e s by the development in a clinical laboratory of a highly sensitive and specific IHC assay. Notably, BAP1 is mutated in the germline, where it predisposes to melanoma and mesothelioma 28, 29, 50, 51 . Given the role of BAP1 in sporadic ccRCC, germline BAP1 mutations may similarly predispose to RCC. In fact, a germline variant (c.121G>A; p.Gly41Ser) was identified in one individual who had two first-degree relatives and one second-degree relative with RCC; this individual had previously been screened for a germline VHL mutation, but no mutation was found. In addition, a recently reported pedigree had one individual with a germline BAP1 mutation who had RCC 51 . Thus, BAP1 mutation in the germline may predispose to RCC, in which case, RCC development may also be initiated by loss of BAP1.
Multiple lines of evidence implicate HCF-1 in BAP1-mediated RCC tumor suppressor function. First, BAP1 binds to and cofractionates with HCF-1. Second, as determined in immunodepletion experiments, the majority of BAP1 is bound to HCF-1. HCF-1 is a very abundant protein 52 , and this may explain why mutant BAP1 does not function as a dominant negative. Third, the growth inhibitory effect of BAP1 is compromised by a mutation that, although not disruptive to protein structure (as determined by retention of deubiquitinating activity), disrupts HCF-1 binding. Finally, the interaction with HCF-1 is unlikely to reflect an abnormal epigenetic state of tumor cell lines in culture, as BAP1 also binds to and cofractionates with HCF-1 in tumorgrafts. Notably, however, the HCF-1 binding motif in BAP1 is not conserved in the Drosophila Calypso protein.
The role of H2Aub1 in ccRCC requires further study. BAP1 binding to HCF-1 was required for the suppression of cell proliferation but was dispensable for H2Aub1 deubiquitination. Thus, these two functions of BAP1-HCF-1 binding and H2Aub1 deubiquitination-can be separated. We did not find a correlation between BAP1 inactivation and global H2Aub1 levels in tumors. Nevertheless, the levels of H2Aub1 were not uniform across tumors, and we cannot rule out the possibility that BAP1 may affect the levels of H2Aub1 at specific sites.
Our studies were greatly aided by the availability of tumorgrafts. Tumorgrafts were instrumental in determining MARs with accuracy and for the identification of putative two-hit tumor suppressor genes. They also made it possible to determine the co-occurrence of mutations in tumor cells, and, when mutations occurred in regions of amplification, they shed light on the temporal sequence of mutation acquisition. Finally, tumorgrafts provided a renewable source of tumor material, allowing us to evaluate the relevance of biochemical observations made in cell lines in culture.
While this manuscript was in preparation, a brief communication reported a list of 12 genes mutated in ccRCC 53 , including TSC1, which we previously showed to be mutated in sporadic ccRCC 18 , and BAP1. The mutation frequency reported for BAP1 was 8%, but a VHL mutation frequency of 27% suggests low sensitivity.
URLs. Bioconductor, http://www.bioconductor.org/; Catalogue of Somatic Mutations in Cancer (COSMIC), http://www.sanger.ac.uk/ genetics/CGP/cosmic/; ImageJ, http://rsbweb.nih.gov/ij/; Integrative Genomics Viewer (IGV), http://www.broadinstitute.org/igv/.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. SNP and gene expression microarray data have been deposited at the Gene Expression Omnibus (GEO) (GSE25540 and GSE36895, respectively). Whole-genome and exome sequences for individuals consenting to the deposit of their information are in the database of Genotypes and Phenotypes (dbGaP) (phs000491).
ONLINE METHODS
Regulatory considerations. All subjects provided written informed consent to a UT Southwestern Institutional Review Board (IRB)-approved protocol for tissue collection for genetic studies. Whole-genome and exome sequences were released in the database of Genotypes and Phenotypes (dbGaP) for those individuals that gave explicit authorization on the consent form.
Annotation. Tumor samples were labeled with a number or a number preceded by a T if those samples were also used for tumorgraft generation. Tumorgrafts were labeled with the same number as tumors with the prefix TG and followed by a cohort c number (when applicable) referring to the tumor passage (for example, c0 for a primary tumorgraft).
Tumor stage was determined on the basis of tumor, node, metastasis (TNM) classification from the American Joint Committee on Cancer. Samples were annotated according to the edition corresponding to the date of surgery. Per the seventh edition, all tumors with lymph node metastases were referred to as pN1.
Tissue selection. ccRCC and adjacent normal kidney samples were frozen fresh in liquid nitrogen and stored at −80 °C. Tumor content and quality was inferred by a pathologist from perpendicular sections immediately flanking 1-3 mm thick fragments that were oriented using pathology dyes (Supplementary Fig. 2c ). For whole-genome sequencing a sample was selected with ~90% tumor content in both sections. For the Discovery Set, 76 ccRCC samples with ≥80% tumor cellularity were selected among 431 fresh-frozen tumor samples from 133 patients. Seven tumor samples and a metastasis with ≥85% tumor cellularity were selected for exome sequencing among 16 patients with tumorgrafts growing in mice 43 . For the Validation Set, 92 ccRCC samples with ≥70% tumor cellularity were selected among 535 fresh-frozen tumor samples from 165 RCC patients. Genomic DNA and RNA were simultaneously extracted from each tissue (detailed in the Supplementary Note). Reference DNA, extracted from either adjacent normal kidney or peripheral blood mononuclear cells (PBMCs), was available for 71/76 tumors in the Discovery Set and 82/92 tumors of the Validation Set.
Whole-genome sequencing of paired-end libraries from tumor and matched normal genomes. Tumor and PBMC samples were processed in a CLIA-certified and College of American Pathologists (CAP)-accredited laboratory. The preparation of short-insert (212-263 bp) Illumina paired-end sequencing libraries, flow cells and clusters has been described previously 54 . Paired-end sequence reads of 100 bases were generated using the Genome Analyzer IIx. Image analysis, base calling and Phred quality scoring were performed using the Illumina analysis pipeline (RTA, v1.5). Sequence reads were filtered out from clusters whose proximity to others resulted in mixed sequence data.
Whole-genome somatic substitution and indel detection.
Single-nucleotide variants (SNVs) from the reference sequence (human NCBI36.1) were determined separately for the tumor and normal genomes using CASAVA, v1.6. Prediction of a homozygous SNV required a minimum allele score of 10 (equivalent to at least three high-quality (Q33) base calls). Additionally, for heterozygous calls, the second allele was required to have a score of at least 6 (equivalent to two Q30 base calls), and the ratio of the two allele scores had to be ≤3, so that allele ratios did not deviate from the expected 1:1 ratio for heterozygous calls. Indels relative to human NCBI36.1 were predicted using GROUPER. SNVs and indels in tumors were only considered as candidate somatic events if the read depth at the equivalent site in the normal genome build was at least 10. SNVs and indels observed in both genomes were subtracted from the tumor calls. Previously known SNPs (those in dbSNP130) were also removed. Indels in the tumor overlapping a contig of assembled shadow reads in the normal genome were removed. The impact of somatic changes on protein-coding and non-coding genes was annotated using Ensembl version 54.
Exome capture and sequencing. Exome capture was performed by Illumina FastTrack using Illumina Truseq exome-target enrichment. Details are provided in the Supplementary Note. Exome mutation detection and validation. The sequences of tumor, metastasis and normal samples were compared to NCBI reference sequence, and SNVs and indels were determined independently using CASAVA, v1.8.0a4, without any filtering. Mutations predicted in tumors that were also present in the corresponding normal samples were eliminated ( Supplementary Table 5 ). Synonymous mutations were removed, and the resulting mutations were inspected visually using the Integrative Genomics Viewer (IGV; see URLs) to confirm their presence in tumor but not normal sequence reads (Supplementary Table 5 ). All genes with recurrent mutations were validated by Sanger sequencing (Supplementary Table 7) . For the remaining genes, a mutation calling accuracy of >95% for 82 mutations would signify >90% accuracy for the whole cohort, according to a cumulative hypergeometric distribution. Sanger sequencing of 82 randomly selected mutations (proportional to the number of mutations in 7 tumors and 1 metastasis) showed 4 false positives (<5%), all of which had been scored on the basis of 2 mutant reads (Supplementary Table 6 ). Among the remaining genes, those with just two mutant reads (three) were inferred to represent false positives (Supplementary Data 2) .
Mutation analyses and mutant allele ratios. SNVs and indels in chromatograms were scored with Mutation Surveyor, v3.30 and v3.98 (Softgenetics), using an overlapping factor of 0.2 and a dropping factor of 0.1. Reference sequences were obtained from NCBI. Only bidirectionally observed somatic mutations are reported. Mutations within 7 nt upstream or downstream of an exon boundary were considered to be splice-site mutations. A somatically acquired PBRM1 variant outside this range (15 nt upstream of exon 8) was not included in the analyses (sample 78).
MARs refer to the fraction of mutant allele for a particular mutation over the sum of mutant and wild-type alleles (MAR of 1, only mutant allele detected; MAR of 0.5, mutant and wild-type alleles detected at similar frequencies). MARs were calculated by measuring the nucleotide intensities of chromatograms using ImageJ (see URLs) (whole-genome data) or with the Mutation Quantifier function of Mutation Surveyor, v3.98 (exome data). For indels, MARs were calculated by taking the average of the measurements of at least five nucleotides. MARs were scored as <0.10 if they accounted for <10% of all alleles but were clearly present in tumorgrafts. For Illumina tracings, MARs were calculated on the basis of the number of mutant over total reads. Copy-number analyses. Genomic DNA was hybridized to Affymetrix SNP Arrays 6.0 at the Genome Science Resource (Vanderbilt University) using standard procedures. Several tumor and tumorgraft SNP arrays were previously evaluated for other purposes and have been reported elsewhere 21 . CEL files were quantile normalized with Partek Genomics Suite 6.5, adjusting for fragment length and probe sequence without background correction. Paired copy numbers for tumors and tumorgrafts were calculated from the intensities of the corresponding normal samples. Genotypes were estimated using the birdseed v2 algorithm in the Affymetrix Genotyping Console 4.0. Regions of allelic imbalance were identified by determining the allele-specific copy number for the primary tumor or tumorgraft with respect to normal DNA using the Partek Genomics Suite. Copy numbers were adjusted for local GC content and were segmented using Circulary Binary Segmentation (CBS) 55 , where log 2 ratios were analyzed with the DNAcopy package of Bioconductor in R (see URLs), considering a type I error (α = 0.001) and a minimum segment size of 5 markers. Maximum and minimum allele-specific copy numbers were segmented independently by CBS.
Establishment and maintenance of tumorgrafts. Tumorgraft studies were approved by the UT Southwestern Institutional Animal Care and Use Committee (IACUC). Fresh tumor fragments (~2 mm in diameter) were implanted in the kidney of NOD/SCID mice as described elsewhere 21 .
Gene expression analyses. RNA samples were labeled with biotin and hybridized to Affymetrix Human Genome U133 Plus 2.0 arrays by the UT Southwestern Microarray Core. Gene expression arrays on 13 of 29 tumors and tumorgrafts were previously evaluated to identify a tumor-specific signature and have been previously reported 21 . CEL intensity files were analyzed as described elsewhere 56 . Probe sets with nonspecific hybridization npg
